$11.63
+0.35 (+3.10%)
Open$11.41
Previous Close$11.28
Day High$11.92
Day Low$11.35
52W High$309.60
52W Low$9.10
Volume—
Avg Volume228.1K
Market Cap65.38M
P/E Ratio—
EPS$-0.56
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+135.7% upside
Current
$11.63
$11.63
Target
$27.41
$27.41
$18.46
$27.41 avg
$44.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.11M | 95.94M | 101.30M |
| Net Income | -3,905,705 | 13.15M | 13.02M |
| Profit Margin | -351.5% | 13.7% | 12.9% |
| EBITDA | -3,913,564 | 20.01M | 19.52M |
| Free Cash Flow | — | 11.25M | 11.45M |
| Rev Growth | — | +8.6% | -0.1% |
| Debt/Equity | 6.70 | 1.02 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |